MedTrace Logo

Efficacy of Simvastatin in Alcoholic Liver Fibrosis

NCT04971577 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-12-04

No results posted yet for this study

Summary

Evaluate the efficacy of simvastatin in reducing liver fibrosis in patients with advanced fibrosis due to alcohol

Conditions

  • Liver Fibrosis
  • Alcohol Abuse

Interventions

DRUG

Simvastatin 40mg

participants will receive a capsule containing 4 tablets simvastatin 10 mg (40 mg total) every 24 hours at night

Sponsors & Collaborators

  • Anna Cruceta

    lead OTHER

Principal Investigators

  • Pere Gines, Md · Hospital Clinic of Barcelona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-22
Primary Completion
2027-03-31
Completion
2027-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04971577 on ClinicalTrials.gov